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Identity 
Other names: HSKM-B; KMT3C; MGC119305; 
ZMYND14 




55913 bp, 12 exons. 
Transcription 




433 amino acids. The protein contains SET domain, 
MYND domain/zinc-finger motif, and cysteine-rich 
post-SET domain. The SET domain is split into two 
segments by a MYND domain. 
Expression 
Wide, highly expressed in heart, brain, liver, kidney, 
thymus, ovary, embryonic tissues (heart,  
hypothalamus) (Brown et al., 2006). 
 
Localisation 
Cytoplasmic and nucleus (Brown et al., 2006). 
Function 
Regulation of transcription as a lysine 
methyltransferase for histone 3, lysine 36 (H3K36) and 
inhibition of p53's transactivation activity as a lysine 
methyltransferase for lysine 370 (K370) of p53 through 
the SET domain (Brown et al., 2006; Huang et al., 
2006). Possibly promotion of cell proliferation and/or 
differentiation through its overexpression/activation-
induced inhibition of p53's transactivation activity. 
Methylation of retinoblastoma (RB) tumor suppressor 
at lysine 860, that is regulated during cell cycle 
progression, cellular differentiation ,and in response to 
DNA damage (Saddic et al., 2010). RB 
monomethylation at lysine 860 provides a direct 
binding site for the transcription repressor L3MBTL1. 
Through interaction with HSP90alpha, SMYD2 histone 
methyltransferase activity and specificity for histone 
H3 at lysine 4 (H3K4) are enhanced in vitro (Abu-
Farha et al., 2008). SMYD2 gain of function is 
correlated with the upregulation of 37 and down 
regulation of 4 genes, the majority of which are 
involved in the cell cycle, chromatin remodelling, and 
transcriptional regulation (Abu-Farha et al., 2008). 
Homology 
Xenopus laevis, Zebrafish, Chicken, Gray short-tailed 
opossum, Mouse, Rat, Rabbit, Pig, Horse, Cattle, Dog, 
White-tufted-ear marmoset, Rhesus monkey, Sumatran 
orangutan, Chimpanzee. 













Esophageal squamous cell carcinoma 
(ESCC) 
Note 
Frequent overexpression of SMYD2 mRNA and 
protein was observed in KYSE150 cells with 
remarkable amplification at 1q32-q41.1 and other 
ESCC cell lines (11/43 lines, 25.6%). Overexpression 
of SMYD2 protein was frequently detected in primary 
tumor samples of ESCC (117/153 cases, 76.5%) as well 
and significantly correlated with gender, venous 
invasion, the pT category in the tumor-lymph node-
metastasis classification and status of recurrence. 
Patients with SMYD2-overexpressing tumors had a 
worse overall rate of survival than those with non-
expressing tumors. Knockdown of SMYD2 expression 
inhibited and ectopic overexpression of SMYD2 
promoted the proliferation of ESCC cells in a TP53 
mutation-independent but SMYD2 expression 
dependent manner (Komatsu et al., 2009). 
Thyroid carcinoma and benign thyroid 
nodule 
Note 
Using differential display-polymerase chain reaction 
method, the gene expression differences between 
benign thyroid nodules (BTNs) and follicular and 
classic variants of papillary thyroid carcinoma (PTC) 
were evaluated in a group of 42 patients (15 BTNs, 14 
follicular variant of PTC and 13 classic variant of
PTC). SMYD2 had lower expression in both carcinoma 
groups than in BTNs (Igci et al., 2011). 
Breast cancer 
Note 
Expression of a group of three genes (MTSS1, RPL37, 
and SMYD2) evaluated by real-time PCR was shown 
to be a potential candidate to predict response to 
neoadjuvant chemotherapy (4 cycles of doxorubicin 
and cyclophosphamide) in breast cancer patients 
(Barros Filho et al., 2010). 
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